• Home
• About us
• Contact

• News
• People
• Products
• Deals
• Organisations

• Twitter
• Newsletter

Advertisement

Person › Details

Menelas Pangalos (AstraZeneca plc (LSE: AZN))

Pangalos, Menelas (AstraZeneca 201303 EVP Innovative Medicines + Early Development Biotech Unit)

 

	Organisation	AstraZeneca plc (LSE: AZN)
	Group	AstraZeneca (Group)
	Product	drug development
	Product 2	drug discovery

Record changed: 2021-09-29

Advertisement

More documents for Menelas Pangalos

• [1] AstraZeneca plc. (6/21/22). "Press Release: Eplontersen Met Co-primary and Secondary Endpoints in Interim Analysis of the NEURO-TTRansform Phase III Trial for Hereditary Transthyretin-mediated Amyloid Polyneuropathy (ATTRv-PN)"....
• [2] AstraZeneca plc. (9/23/21). "Press Release: AstraZeneca to Discover and Develop Self-amplifying RNA Therapeutics in New Collaboration with VaxEquity. AstraZeneca Will Invest in VaxEquity, an Imperial College Spin-off"....
• [3] VaxEquity Ltd.. (9/23/21). "Press Release: VaxEquity Announces Strategic Collaboration with AstraZeneca to Commercialise Self-Amplifying RNA Platform". London....
• [4] Redx Pharma plc. (8/4/20). "Press Release: Redx Signs Out Licensing Agreement with AstraZeneca". Alderley Park....
• [5] Silence Therapeutics plc. (3/25/20). "Press Release: Silence Therapeutics Announces Collaboration with AstraZeneca to Discover and Develop siRNA Therapeutics for Cardiovascular, Renal, Metabolic and Respiratory Diseases". London....
• [6] AstraZeneca plc. (8/22/19). "Press Release: Roxadustat Approved in China for the Treatment of Anaemia in Non-dialysis-dependent Patients with Chronic Kidney Disease"....
• [7] AstraZeneca plc. (8/20/19). "Press Release: Farxiga Met Primary Endpoint in Landmark Phase III DAPA-HF Trial for the Treatment of Patients with Heart Failure"....
• [8] AstraZeneca plc. (1/7/19). "Press Release: AstraZeneca Announces Organisational Changes"....
• [9] AstraZeneca plc. (12/10/18). "Press Release: AstraZeneca and Cancer Research UK Launch Functional Genomics Centre to Accelerate the Discovery of New Medicines"....
• [10] AstraZeneca plc. (6/12/18). "Press Release: Update on Phase III Clinical Trials of Lanabecestat for Alzheimer’s Disease. Independent Data Monitoring Committee Advises Lanabecestat Is Unlikely to Meet Primary Endpoints, Leading to Decision to Discontinue...

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2022. Made in Germany.